Smith & Nephew SNATS(SNN) is having a Dividend Yield of 1.98% with the Annual cash Dividend per share of $0.61. The last quarter cash dividend per share pay out was $0.24. Smith & Nephew SNATS has a 5 year average dividend yield of 1.76% and the stock has a Indicated annual dividend of $0.61. Smith & Nephew SNATS(SNN) formally announced its most recent dividend on September 1, 2016 with a Dividend per share of $0.24. The new indicated annual dividend based on announced dividend per share is $0.61. The dividend yield based on the forward looking indicated annual dividend is 1.98%. The 5 year historical dividend growth of Smith & Nephew SNATS(SNN) is at the rate of 14.05% while the R-Squared dividend growth is 0.79. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
Smith & Nephew SNATS, Inc. (NYSE:SNN) rose 0.13% or 0.04 points on Thursday and made its way into the gainers of the day. After trading began at $30.53 the stock was seen hitting $30.69 as a peak level and $30.48 as the lowest level. The stock ended up at $30.66. The daily volume was measured at 584,944 shares. The 52-week high of the share price is $35.38 and the 52-week low is $26.965. The company has a market cap of $14,034 million. Shares of Smith & Nephew plc rose by 0.26% in the last five trading days and 0.95% for the last 4 weeks. Smith & Nephew plc is up 11.49% in the last 3-month period. Year-to-Date the stock performance stands at 1.93%.
Currently the company Insiders own 1% of Smith & Nephew SNATS, Inc. shares according to the proxy statements. Institutional Investors own 6.14% of Smith & Nephew SNATS, Inc. shares. Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Smith & Nephew plc (ADR) was Initiated by HSBC Securities to Hold on Jan 19, 2017. Smith & Nephew plc (ADR) was Upgraded by Morgan Stanley to Overweight on Dec 8, 2016.
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world